-- Cerus (CERS) said Monday it has signed a new four-year supply agreement with the French Blood Establishment for the Intercept blood system.
The agreement covers the use of the system for platelets and plasma as well as the LED-based INT200 illumination device, the company said.
Financial details were not provided.
Cerus shares were up 2.3% in morning trading.
Price: $2.03, Change: $+0.05, Percent Change: +2.53%